Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials

Affiliations

¹ Former Chairman of the Department of Medical Oncology, Inselspital and University of Bern, Bern, Switzerland.
² Consultant Medical Oncologist, University College Cork, Cork, Ireland.
³ Medical Oncologist, Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium.
⁴ CRAB Cancer Research and Biostatistics, Seattle, Washington, USA.
⁵ University of British Columbia Faculty of Medicine, 2775 Laurel Street, Vancouver, British Columbia, Canada.

Editorial

Martin F Fey et al. Curr Opin Oncol. 2024.

. 2024 Sep 1;36(5):418-420.

doi: 10.1097/CCO.0000000000001056. Epub 2024 Aug 8.

¹ Former Chairman of the Department of Medical Oncology, Inselspital and University of Bern, Bern, Switzerland.
² Consultant Medical Oncologist, University College Cork, Cork, Ireland.
³ Medical Oncologist, Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium.
⁴ CRAB Cancer Research and Biostatistics, Seattle, Washington, USA.
⁵ University of British Columbia Faculty of Medicine, 2775 Laurel Street, Vancouver, British Columbia, Canada.

No abstract available

References

1. Garcia S, Bisen A, Yan J, et al. Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity. J Thorac Oncol 2017; 12:1489–1495.
1. www.ich.org .
1. www.meddra.org .
1. Wakao R, Taavola H, Sandberg L, et al. Data-driven identification of adverse event reporting patterns for Japan in VigBase, the WHO global database of individual case safety reports. Drug Saf 2019; 42:1487–1498.
1. O’Reilly S, Murphy V, Mulroe E, et al. The SARS-CoV-2 pandemic and cancer trials ireland: impact, resolution and legacy. Cancers 2022; 14:2247–2257.